Topamax and Hydrocephalus - a phase IV clinical study of FDA data

Summary:

Hydrocephalus is reported as a side effect among people who take Topamax (topiramate), especially for people who are male, 2-9 old, have been taking the drug for 1 - 6 months also take Synthroid, and have Growth hormone deficiency.

The phase IV clinical study analyzes which people have Hydrocephalus when taking Topamax. It is created by eHealthMe based on reports of 54,158 people who have side effects when taking Topamax from the FDA, and is updated regularly.

What is Topamax?

Topamax has active ingredients of topiramate. It is often used in migraine. eHealthMe is studying from 58,954 Topamax users. Check the latest studies of Topamax.

What is Hydrocephalus?

Hydrocephalus (water on the brain) is found to be associated with 761 drugs and 1,369 conditions by eHealthMe. Check the latest studies of Hydrocephalus.

On Jul, 22, 2026

54,158 people reported to have side effects when taking Topamax.
Among them, 63 people (0.12%) have Hydrocephalus.

Among these 63 people:

How long have people been on Topamax when they have Hydrocephalus? *

What is the gender of people who have Hydrocephalus when taking Topamax? *

female: 42.86 %
male: 57.14 %

What is the age of people who have Hydrocephalus when taking Topamax? *

What are other drugs people take besides Topamax? *

What are other side effects people have besides Hydrocephalus? *

Hypothalamo-Pituitary Disorder (loss of function in an endocrine gland due to failure of the pituitary gland to secrete hormones which stimulate that gland's function): 11 people, 17.46%
Therapeutic Response Unexpected: 11 people, 17.46%
Drug Exposure During Pregnancy: 10 people, 15.87%
Neurogenic Bladder (the normal function of the bladder is to store and empty urine in a coordinated, controlled fashion): 7 people, 11.11%
Emotional Disorder: 7 people, 11.11%
Neurogenic Bowel (impairment of the gastrointestinal and anorectal function from a lesion in the nervous system, resulting in failure to evacuate): 6 people, 9.52%
Stress And Anxiety: 6 people, 9.52%
Headache (pain in head): 6 people, 9.52%
Body Temperature Fluctuation: 6 people, 9.52%
Developmental Delay: 5 people, 7.94%

What are the existing conditions these people have? *

Growth Hormone Deficiency: 14 people, 22.22%
Foetal Exposure During Pregnancy (exposing your unborn child to contraindicated in pregnancy leads birth defect): 11 people, 17.46%
Drug Exposure During Pregnancy: 5 people, 7.94%
Anaesthesia: 4 people, 6.35%
Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 4 people, 6.35%
Cataplexy (loss of muscle tone accompanied by full conscious awareness): 4 people, 6.35%
Depression: 3 people, 4.76%
Infection: 2 people, 3.17%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 3.17%
Sleep Disorder: 2 people, 3.17%

* Approximation only. Some reports may have incomplete information.

Do you take Topamax and have Hydrocephalus?

- Check whether Hydrocephalus is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Topamax:

Topamax (58,954 reports)

Hydrocephalus treatments and more:

Hydrocephalus (6,876 reports)

Browse all side effects of Topamax:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hydrocephalus:

Hydrocephalus (761 drugs)

Browse all the conditions that are associated with Hydrocephalus:

Hydrocephalus (1,369 conditions)

Related publications that referenced our studies

Baloch M, Siddiqui MA, "Topiramate induced sudden loss of vision", JPMA, 2012 Oct .
Kocamaz, M., & Karadag, O., "Topiramate-Induced Acute Myopia, Diplopia, and Photosensitivity: A Case Report", Beyoglu Eye Journal, 2019 Jan .
Baloch M, Siddiqui MA, "Topiramate induced sudden loss of vision", JPMA, 2012 Oct .
Kocamaz, M., & Karadag, O., "Topiramate-Induced Acute Myopia, Diplopia, and Photosensitivity: A Case Report", Beyoglu Eye Journal, 2019 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on topiramate (the active ingredients of Topamax) and Topamax (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.